Sign In
Buy CERT
$5.60
-0.0200 (-0.356%)
At Close: Jun 03, 2026
Certara Reports Second Quarter 2025 Financial Results
04:15pm, Wednesday, 06'th Aug 2025
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal y
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
02:00am, Monday, 04'th Aug 2025
Certara today announced that the European Medicines Agency has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
04:15pm, Thursday, 31'st Jul 2025
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D.
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Wednesday, 30'th Jul 2025
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Friday, 11'th Jul 2025
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Certara: Ideally Positioned To Benefit From IT Innovation In Life Sciences
03:09am, Friday, 11'th Jul 2025
Certara is a leader in Model-Informed Drug Development (MIDD), offering essential software and services that reduce drug development costs and time. The company's diversified software portfolio and gr
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
04:15pm, Wednesday, 09'th Jul 2025
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second q
Certara Announces Expansion of Clinical Technology Collaboration with Merck
08:00am, Tuesday, 08'th Jul 2025
RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
09:10am, Saturday, 28'th Jun 2025
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript
07:22pm, Monday, 05'th May 2025
Certara, Inc. (NASDAQ:CERT ) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Offi
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates
06:51pm, Monday, 05'th May 2025
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.10 per share a year ago.
Certara Reports First Quarter 2025 Financial Results
04:15pm, Monday, 05'th May 2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal yea
Certara to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 29'th Apr 2025
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the follow
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
11:05am, Monday, 28'th Apr 2025
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Momentum Stocks That Could Soar Post-Market Volatility
08:02am, Monday, 21'st Apr 2025
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish
